Category - Markets

Stifel initiated coverage of Vanda Pharmaceuticals (NASDAQ:VNDA) with a “buy” rating and $30 price target. The stock closed at $18.45 on Sept. 12. “We like the near-term catalyst path for Vanda shares as we believe...

J.P. Morgan launched coverage of ObsEva SA (NASDAQ:OBSV) with an “overweight” rating and a price target of $29 at the end of 2019. The stock closed at $14.40 on Sept. 12. “We view ObsEva as an underappreciated, emerging...

Ladenburg Thalmann initiated coverage of Arch Therapeutics (OTCQB:ARTH) with a “buy” rating and price target of $1.25. The stock closed at 46 cents on Sept. 11. The company is developing a novel hemostat to control skin...

Ladenburg Thalmann launched coverage of Novus Therapeutics (NASDAQ:NVUS) with a “buy” rating and $12 price target. The stock closed at $4.53 on Sept. 10. Novus is developing a novel treatment for otitis media (OM)...

H.C. Wainwright raised its price target for Avid Bioservices (NASDAQ:CDMO) to $11 from $6, saying the company’s business development continues to ramp up and reap rewards. The stock closed at $7.17 on Sept. 10. Avid is...

H.C. Wainwright initiated coverage of Melinta Therapeutics (NASDAQ:MLNT) with a “buy” rating and $14 price target. The stock closed at $4.30 on Sep. 10. Melinta is focused on its four marketed drugs, especially its two...

Ladenburg Thalmann launched coverage of Cyclacel Pharmaceuticals (NASDAQ:CYCC) with a “buy” rating and $6.25 price target. The stock closed at $1.43 on Sept. 6. “We believe CYC065, the company’s CDK 2/9 inhibitor, has...

Roth Capital Partners initiated coverage of Obalon Therapeutics (NASDAQ:OBLN) with a “buy” rating and $6 price target. The stock closed at $2.91 on Sept. 5. Obalon offers the Obalon Balloon System, the first and only...

Piper Jaffray resumed coverage of Bovie Medical (NYSE American:BVX) with an “overweight” rating and $8 price target after the company completed the sale of its core business. The stock finished at $6.14 on Sept. 5...

H.C. Wainwright lowered its price target for Histogenics (NASDAQ:HSGX) to $2 from $3.50, but maintained its “buy” rating, after the company missed its primary endpoint in a Phase 3 study of NeoCart for knee cartilage...